Government halts drug production at 31 firms due to quality control non-adherence
The Centre has halted the production of drugs in 31 companies and revoked or suspended product licenses for 50 firms due to their failure to comply with quality control regulations. Moreover, 73 firms have received show-cause notices, and warning letters have been issued to 21 companies.
These actions result from a nationwide inspection conducted by drug regulatory bodies, targeting drug manufacturing units identified as being at risk of producing Not of Standard Quality (NSQ), adulterated, or spurious drugs. The inspections were prompted by recent controversies surrounding alleged adulteration in certain products, primarily cold and cough syrups exported abroad.
On Tuesday, Union Minister of chemicals and fertilisers, Mansukh Mandaviya held a meeting with representatives of several pharmaceutical companies on the matter and said, “It is important for MSME pharma cos. to be alert to quality of drugs and expeditiously move towards good manufacturing processes through self-regulation.”
He also directed the DCGI to take stringent action against all companies that make spurious drugs. “There shall be no compromise with the quality of drugs manufactured in India”, he stated.
post_id:
uld_count:
Cookie not set
Like
Dislike
Value 1: 0
Value 2: 10
